Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Han Hu

Showing results (781-790 of 793) with videos related to

Pageof 80
Sort By:
Journal of the National Cancer Institute|October 23, 2020
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaYuan Lei, Ying-Qin Li, Wei Jiang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 26, 2007
[Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma]Xiao-dong Huang, Jun-lin Yi, Li Gao, et al.
American Journal of Human Genetics|May 21, 2013
Germline BAP1 mutations predispose to renal cell carcinomasTatiana Popova, Lucie Hebert, Virginie Jacquemin, et al.
Nature Genetics|July 16, 2002
Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4Bing-Jian Feng, Wei Huang, Yin Yao Shugart, et al.
Journal of Medical Genetics|February 7, 2013
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variantsHanne Eknes Puntervoll, Xiaohong R Yang, Hildegunn Høberg Vetti, et al.
Circulation|January 20, 2022
Circulating Metabolome and White Matter Hyperintensities in Women and MenEeva Sliz, Jean Shin, Shahzad Ahmad, et al.
The Lancet. Oncology|October 1, 2016
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trialYing Sun, Wen-Fei Li, Nian-Yong Chen, et al.
International Journal of Cancer|January 8, 2019
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trialWen-Fei Li, Nian-Yong Chen, Ning Zhang, et al.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
Pageof 80

Showing results (781-790 of 793) with videos related to

Sort By:
Pageof 80
Journal of the National Cancer Institute|October 23, 2020
A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal CarcinomaYuan Lei, Ying-Qin Li, Wei Jiang, et al.
Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]|July 26, 2007
[Multi-center phase II clinical trial of humanized anti-epidermal factor receptor monoclonal antibody h-R3 combined with radiotherapy for locoregionally advanced nasopharyngeal carcinoma]Xiao-dong Huang, Jun-lin Yi, Li Gao, et al.
American Journal of Human Genetics|May 21, 2013
Germline BAP1 mutations predispose to renal cell carcinomasTatiana Popova, Lucie Hebert, Virginie Jacquemin, et al.
Nature Genetics|July 16, 2002
Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4Bing-Jian Feng, Wei Huang, Yin Yao Shugart, et al.
Journal of Medical Genetics|February 7, 2013
Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variantsHanne Eknes Puntervoll, Xiaohong R Yang, Hildegunn Høberg Vetti, et al.
Circulation|January 20, 2022
Circulating Metabolome and White Matter Hyperintensities in Women and MenEeva Sliz, Jean Shin, Shahzad Ahmad, et al.
The Lancet. Oncology|October 1, 2016
Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trialYing Sun, Wen-Fei Li, Nian-Yong Chen, et al.
International Journal of Cancer|January 8, 2019
Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trialWen-Fei Li, Nian-Yong Chen, Ning Zhang, et al.
Lancet (London, England)|June 10, 2021
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu-Pei Chen, Xu Liu, Qin Zhou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 16, 2022
Final Overall Survival Analysis of Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma: A Multicenter, Randomized Phase III TrialYuan Zhang, Lei Chen, Guo-Qing Hu, et al.
Pageof 80